The University of Oxford researchers have leveraged Clario’s Precision Motion Opal wearable sensor technology for a study to understand motor symptom progression in individuals with Parkinson’s disease.

This advancement is anticipated to hold significant potential for neuroscience clinical trials and future treatments.

By conducting the comprehensive study, which was funded by UCB Pharma, researchers were able to track the motor symptom progression in these individuals better compared to conventionally used clinical rating scales using Clario’s machine learning and wearable sensors.

It was found that wearable technology identified disease progression much faster than the conventional approach.

Clario’s scientific and technical knowledge was used to gather accurate digital movement endpoints, leading to the early detection of disease progression.

This will help speed up the development of new Parkinson’s disease medications and potentially enable earlier intervention for patients with this condition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The University of Oxford study was led by Chrystalina Antoniades, an associate professor of neuroscience, clinical neurology.

It is a part of the Oxford Quantification in Parkinsonism project and it utilised Clario’s Precision Motion Opal wearable sensors to record motor impairment in individuals with Parkinson’s disease and Progressive Supranuclear Palsy.

Clario medical and scientific affairs vice-president Kristen Sowalsky said: “We are honoured to support professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field.

“This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson’s disease progression more accurately and assess the efficacy of early therapeutic intervention.”